Circulation:糖酵解代谢与肺动脉高压基因调控的新发现

2021-09-28 刘少飞 MedSci原创

肺动脉高压 (PAH) 是一种进行性疾病,其中平滑肌细胞 (SMC) 的增殖导致肺动脉逐渐闭塞,导致血流阻力增加并最终导致右心衰竭。目前的疗法试图扩张肺动脉,但没有解决闭塞性重塑的机制。

众所周知,在家族性 PAH 中,70% 至 80% 的受影响者具有 BMPR2(骨形态发生受体 2)突变。这些突变也占特发性 PAH 散发病例的 20%,但即使在没有已知突变的患者中,或者当 PAH 是其他医学疾病的并发症时,BMPR2 表达或信号传导的缺陷也很明显。由于肺动脉内皮细胞 (PAEC) 中 BMPR2 缺陷可以促进生长因子的表达和释放以驱动 PASMC 的增殖,因此 PASMC 中 BMPR2 信号传导的减少也直接有助于其增殖的增强。代谢改变提供了影响染色质结构的底物,以调节决定健康和疾病中细胞功能的基因表达。肺动脉高压中导致新内膜形成的平滑肌细胞(SMC)增高增殖是其疾病的特征。糖酵解增加与SMC的增殖表型明确有关。

研究题目:ALDH1A3 Coordinates Metabolism with Gene Regulation in Pulmonary Arterial Hypertension.

期刊年卷:Circulation 2021 Mar 25; 

通讯作者:Pro.Marlene Rabinovitch from Stanford University

临床儿科心脏病学 肺血管领域全球知名教授学者

斯坦福大学贝蒂·艾琳·摩尔儿童心脏中心基础科学与工程计划主任

维拉·莫尔顿·沃尔肺血管疾病中心研究人员

发表论文超过100余篇,被引13000多次

在整个领域具有很高的学术地位及学科影响力

研究方法:携带和不携带BMPR2突变的PAH患者中,提取肺动脉SMC,通过RNA测序,然后发现其增生和糖酵解代谢所需的基因(下图)。差异表达基因的评估将代谢作为主要途径,而PAH PASMC中代谢水平最高的代谢基因是醛脱氢酶家族1成员3(ALDH1A3),该酶以前与癌细胞和系统性血管SMC中的糖酵解和增殖有关。研究确定了这些功能在PAH PASMC中是否为ALDH1A3依赖性的,以及在转基因小鼠中肺动脉高压的发展是否需要ALDH1A3。ALDH1A3在PAH PASMC中的核定位使研究者探索该酶是否以及如何协调调节PAH PASMC中的基因表达和代谢。

研究结果:与对照PASMC相比,PAH中ALDH1A3的mRNA和蛋白增加,而ALDH1A3则具有高度的增殖和糖酵解特性。特异性SMC中敲除Aldh1a3基因的小鼠在缺氧诱导下,未发生肺动脉肌化或肺动脉高压。核中ALDH1A3将乙醛转化为乙酸酯,从而生成乙酰辅酶A,从而使H3K27乙酰化,成为活性增强剂。这使得经由乙酰基转移酶KAT2B在核因子Y(NFY)A结合位点处进行染色质修饰,并允许NFY介导ALDH1A3依赖性增殖和糖酵解所需的细胞周期和代谢基因的转录。PAH中BMPR2的基因突变使得SMC中上调ALDH1A3,PAH PASMC中NFYA和ALDH1A3的转录是β-catenin依赖性的。

研究结论:该研究发现了一个代谢转录轴,可以解释分裂细胞如何利用ALDH1A3协调其能量需求与SMC增殖所需基因的表观遗传和转录调控。他们认为选择性在PAH SMC中破坏ALDH1A3而不是在EC中的关键作用是重要的治疗考虑因素。

 

文章出处:Li D. ALDH1A3 Coordinates Metabolism With Gene Regulation in Pulmonary Arterial Hypertension. Circulation. 2021 May 25;143(21):2074-2090. DOI: 10.1161/CIRCULATIONAHA.120.048845. Epub 2021 Mar 25. PMID: 33764154; PMCID: PMC8289565.

 

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1921324, encodeId=4ed51921324b7, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Thu Apr 07 12:45:00 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1925381, encodeId=0ece192538120, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Dec 14 15:45:00 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275786, encodeId=83ac12e578696, content=<a href='/topic/show?id=22a8e68696b' target=_blank style='color:#2F92EE;'>#糖酵解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76869, encryptionId=22a8e68696b, topicName=糖酵解)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Tue Sep 28 07:45:00 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557668, encodeId=8a72155e66839, content=<a href='/topic/show?id=530341903b2' target=_blank style='color:#2F92EE;'>#基因调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41903, encryptionId=530341903b2, topicName=基因调控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Tue Sep 28 07:45:00 CST 2021, time=2021-09-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1921324, encodeId=4ed51921324b7, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Thu Apr 07 12:45:00 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1925381, encodeId=0ece192538120, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Dec 14 15:45:00 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275786, encodeId=83ac12e578696, content=<a href='/topic/show?id=22a8e68696b' target=_blank style='color:#2F92EE;'>#糖酵解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76869, encryptionId=22a8e68696b, topicName=糖酵解)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Tue Sep 28 07:45:00 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557668, encodeId=8a72155e66839, content=<a href='/topic/show?id=530341903b2' target=_blank style='color:#2F92EE;'>#基因调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41903, encryptionId=530341903b2, topicName=基因调控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Tue Sep 28 07:45:00 CST 2021, time=2021-09-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1921324, encodeId=4ed51921324b7, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Thu Apr 07 12:45:00 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1925381, encodeId=0ece192538120, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Dec 14 15:45:00 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275786, encodeId=83ac12e578696, content=<a href='/topic/show?id=22a8e68696b' target=_blank style='color:#2F92EE;'>#糖酵解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76869, encryptionId=22a8e68696b, topicName=糖酵解)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Tue Sep 28 07:45:00 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557668, encodeId=8a72155e66839, content=<a href='/topic/show?id=530341903b2' target=_blank style='color:#2F92EE;'>#基因调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41903, encryptionId=530341903b2, topicName=基因调控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Tue Sep 28 07:45:00 CST 2021, time=2021-09-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1921324, encodeId=4ed51921324b7, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Thu Apr 07 12:45:00 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1925381, encodeId=0ece192538120, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Dec 14 15:45:00 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275786, encodeId=83ac12e578696, content=<a href='/topic/show?id=22a8e68696b' target=_blank style='color:#2F92EE;'>#糖酵解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76869, encryptionId=22a8e68696b, topicName=糖酵解)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Tue Sep 28 07:45:00 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557668, encodeId=8a72155e66839, content=<a href='/topic/show?id=530341903b2' target=_blank style='color:#2F92EE;'>#基因调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41903, encryptionId=530341903b2, topicName=基因调控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Tue Sep 28 07:45:00 CST 2021, time=2021-09-28, status=1, ipAttribution=)]

相关资讯

AJRCCM:基质金属蛋白酶-8与肺动脉高压,下一个国自然基金?

肺动脉高压 (PH) 是一种极其严重的心肺系统的疾病,其预后差,尽管经过目前靶向药物治疗,患者五年的生存率在50%左右。肺动脉高压领域急需新的药物靶点,开启治疗的新时代。

AJRCCM:补体系统与肺动脉高压,国自然新的研究思路?

肺动脉高压(PH)是一种危及生命的心肺疾病,炎症和免疫已成为关键的早期致病因素。尽管肺动脉高压(PAH)的促炎过程是广泛研究的焦点,但其启动机制仍不清楚。

Cardiovasc Res: 我们要更加关注右心衰竭-转录因子Hand2

与肺动脉高压相关的右室衰竭使3 年内的长期生存率降低至55%,与左心室 (LV) 相比,右心室 (RV) 衰竭的病理生理学研究仍落后于相关的高死亡率和发病率。

JHLT:基于体外膜氧合技术,肺动脉高压 患者具有较低的移植率?

肺移植的供体分配会严重影响等待肺移植病人的未来,如何分配才能让更多的人收益?

时隔六年,又一重大发现发表于《新英格兰杂志》: Sotatercept用于治疗肺动脉高压

​肺动脉高压(PAH)的特征是肺血管重构,细胞增殖和长期预后不良。BMP信号通路的功能异常与遗传性和特发性PAH相关。

AJRCCM:晚期肺动脉高压阻塞性肺功能的演变

肺动脉高压 (PAH) 的特征是肺动脉阻抗增加,导致运动不耐受和右心衰竭。 随着针对右心衰竭的治疗方法的改进,人们对 PAH 降低运动能力的新途径越来越感兴趣,这是一个关键的治疗目标。